TargEDys

What TargEDys does

TargEDys is a French biotechnology company founded in 2015 that develops functional food, medical food, and medical products targeting the gut microbiota's ability to regulate appetite. The company is headquartered in Saulx-les-Chartreux, France, and operates with a small team of 11-50 employees. The company was co-founded by Pierre Dechelotte and Serguei Fetissov, with Gregory Lambert serving as CEO and Philippe Lavielle as Chairman of the Board. The co-founders' scientific backgrounds in clinical nutrition and microbiology form the foundation of the company's microbiome-based approach to metabolic health.

TargEDys has raised approximately $10.26 million across two disclosed funding rounds: a 2016 round of $6.53 million co-led by Pontifax and Seventure Partners, and a 2017 round of $3.73 million led by Zaluvida Ventures, with additional participation from NCI, NCI Gestion, Zaluvida Ventures, and Normandie Incubation. The company operates within the broader probiotics and microbiome therapeutics market, where the France and Germany probiotic food supplements market is projected to grow from US$423.84 million in 2025 to US$748.42 million by 2033 (8.05% CAGR), and the global dietary supplements market is projected to grow from US$86.77 billion in 2023 to US$182.52 billion by 2032 (8.73% CAGR).

The company monetizes through a dual-channel model spanning functional food products targeting consumer markets and medical food/medical products distributed via regulated healthcare channels. Specific revenue figures, pricing models, customer concentration, distribution partner details, and product launch data are not disclosed in available sources. The company's scientific positioning around microbiome-based appetite regulation represents a differentiated approach to metabolic health, though commercialization scale, recent operational signals, and technology/AI capabilities are not evident in the provided data.

Name

TargEDys

Legal name

Biocodex

Website

https://targedys.com

Company type

Private

Founded year

1955

Operating status

Operating

Headcount range

11–50 employees

Short description

TargEDys is a French biotech company founded in 2015 that develops functional food, medical food, and medical products to regulate appetite through the gut microbiota, targeting consumer and clinical markets for metabolic health.

Ownership category

akta.pro rank

Product category

Microbiome-based Functional Food and Medical Food

NAICS

Snack Food Manufacturing (31191)

SIC

Food And Kindred Products (2000)

akta.pro primary industry

Palatants, Flavors & Sweeteners (Intake Enhancers) (AFADAKAL)

Keywords

• Microbiome-based therapeutics
• Functional food development
• Medical food products
• Appetite regulation science
• Gut microbiota research

Headquarters

HQ city

Saulx-les-chartreux

HQ country

France

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical product sales: Revenue generated from pharmaceutical products including probiotics, women's health products, and treatments for rare diseases. Products distributed through subsidiaries and distribution partners across 100+ countries.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels2 records

Core offering

TargEDys develops functional food, medical food, and medical products designed to harness the gut microbiota's ability to regulate appetite. The company applies microbiome science to create nutritional and therapeutic interventions targeting satiety and metabolic health. Its work is positioned at the intersection of nutrition, microbiology, and metabolic disease.

Differentiator

Problem solved

Functional benefit

Brands

• Saccharomyces boulardii CNCM I-745: World's first probiotic yeast strain marketed by Biocodex, forming the foundation of the company's heritage

Products and services

• Microbiota-based functional food products Functional food products developed by TargEDys to harness the gut microbiota's ability to regulate appetite, intended for nutrition and metabolic health applications.
• Microbiota-based medical food products Medical food products developed by TargEDys that leverage microbiome science for appetite regulation in patients with specific nutritional or metabolic needs.
• Microbiota-based medical products Medical products developed by TargEDys based on the gut microbiota's ability to regulate appetite, positioned for therapeutic use in metabolic and appetite-related disorders.

Named customers1 record

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Three partnerships are on record, tiered core and minor.

• THX PharmacoreStrategic or Co-development Partner · 1 January 2025Strategic licensing agreement covering two drug candidates targeting three rare diseases: Batten disease, Gaucher disease, and Niemann-Pick type C. Reinforces Biocodex's commitment to addressing high unmet medical needs in rare diseases.
• Beyond Batten Disease FoundationcoreStrategic or Co-development PartnerCollaboration to support the CLN3 Batten community on International Batten Disease Awareness Day. Joint advocacy and awareness efforts for Batten disease.
• Startups (Investing in Startups program)minorStrategic or Co-development PartnerBiocodex invests in startups through its investing in startups initiative, supporting innovation in healthcare and biotechnology sectors.

Scale indicators8 records

Recent moves3 records

Expansion highlights2 records

Direct peers

• YSOPIA Bioscience: French microbiome biotech developing live biotherapeutic products for obesity and metabolic diseases using Hafnia alvei. Directly comparable to TargEDys on target indication (appetite/metabolic), mechanism (microbiome-based), geography (France), and stage (clinical-stage).
• Pendulum Therapeutics: US-based probiotics company developing targeted microbiome interventions for metabolic conditions including type 2 diabetes and weight management. Direct competitor in the probiotic-for-appetite niche with consumer-grade positioning.
• Vedanta Biosciences: Clinical-stage microbiome therapeutics company developing defined bacterial consortia for metabolic, autoimmune, and infectious diseases. Comparable as a microbiome therapeutics platform pursuing regulated product pathways.
• 4D pharma: Clinical-stage microbiome therapeutics company developing live biotherapeutics across oncology, respiratory, and metabolic indications. Comparable as a regulated-path microbiome therapeutics developer competing for similar investor and partner mindshare.
• Yakult Honsha: Global probiotic functional beverage company built around Lactobacillus casei Shirota. Comparable as the dominant consumer-facing probiotic brand and benchmark for functional food commercialization of microbiome science.

Broad incumbents

• Biocodex: Family-owned French pharmaceutical company commercializing Saccharomyces boulardii CNCM I-745 with €677M revenue and 100+ country distribution. Closely adjacent in microbiota science and the most likely strategic acquirer of TargEDys assets.
• Danone: Global food and dairy major with a portfolio of probiotic functional foods (Actimel, Activia) and medical nutrition brands (Nutricia). Comparable as the dominant scaled player TargEDys would compete against in functional food and medical nutrition channels.
• Nestlé Health Science: Global medical nutrition and functional food business with explicit microbiome and metabolic health strategies. Comparable as the leading medical food platform and a likely acquirer of microbiome assets.

Others

• Chr. Hansen: Global bioscience company supplying probiotic strains and cultures to food, supplement, and pharma customers. Comparable as a key supplier/enabler of microbiome products and potential B2B partner for TargEDys's strain development.
• Lesaffre: French global yeast and fermentation company with a dedicated microbiome/health ingredients division. Comparable as an enabler/supplier of yeast-based probiotic ingredients and a potential strategic partner given French proximity.

Market position

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/targedys
• LinkedInlinkedin.com/company/targedys

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries15 records

Funding overview

Funding rounds3 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TargEDys